|
Apr 18
|
Engineering a Cool Career in Biotech - and Volunteering Along the Way
|
|
Apr 18
|
QQQ Has Some Inexpensive Growth Stocks
|
|
Apr 17
|
Evidence Supports Sequencing As First-Line Rare Disease Diagnostic
|
|
Apr 15
|
European Commission approves Illumina’s proposed Grail split
|
|
Apr 12
|
Illumina's planned divestment of GRAIL approved by the European Commission
|
|
Apr 12
|
UPDATE 1-EU approves Illumina's plan to divest cancer test maker Grail
|
|
Apr 12
|
EU approves Illumina's plan to divest cancer test maker Grail
|
|
Apr 10
|
Search for Cancer Blood Test Continues Despite Illumina-Grail Deal’s Failure
|
|
Apr 10
|
Illumina CFO steps down amid executive shakeup
|
|
Apr 9
|
UPDATE 2-Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed
|
|
Apr 9
|
Illumina CFO Goswami to depart, former Summit Therapeutics exec Dhingra to succeed
|
|
Apr 9
|
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
|
|
Apr 5
|
Nasdaq’s Nosebleed Section: 3 Expensive Stocks to Sell Before It’s Too Late
|
|
Apr 5
|
Why More Clinical Labs Are Turning to Whole-Genome Sequencing for Cancer
|
|
Apr 4
|
Illumina to Announce First Quarter 2024 Financial Results on Thursday, May 2, 2024
|
|
Apr 2
|
Giving Students a New Window on Genomic Technologies
|
|
Mar 30
|
20 Foods To Reduce Cancer Risk
|
|
Mar 27
|
Is Illumina, Inc. (NASDAQ:ILMN) Trading At A 36% Discount?
|
|
Mar 26
|
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
|
|
Mar 25
|
Court adviser sides with Illumina in EU row that triggered Grail fine
|